Musa Ak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Musa Ak has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Kaya
Inonu University, Turgut Ozal Medical Center, Department of Hematology, Malatya, Turkey
2 shared publications - Ahmet Sarıcı
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
2 shared publications - Emin Kaya
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
2 shared publications - Ilhami Berber
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
2 shared publications - İrFan Kuku
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
2 shared publications - Mehmet Ali Erkurt
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
2 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2615
Early Bacterial Bloodstream Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Microbiology and Outcomes in a Single Turkish Center
Background/Objectives: Bloodstream infections (BSIs) are a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and reported incidence depends on how skin commensals are adjudicated. We describe the epidemiology, microbiology, risk factors, and survival impact of early (day 0–30) bacterial BSI at a Turkish transplant center. Methods: We retrospectively studied 155 consecutive allo-HSCT episodes in 153 adults (April 2017–January 2026). Single-isolate coagulase-negative staphylococci (CoNS) were classified as contaminants. Cumulative incidence was estimated with the Aalen–Johansen estimator and survival with day-30 landmark and time-dependent Cox models. Results: Bacterial BSI occurred in 20 episodes (30-day cumulative incidence 12.9%, 95% CI 8.2–18.7) at a median of 14 days; counting single-isolate CoNS would have raised incidence to 40.0%. Of 22 isolates, 15 (68.2%) were Gram-negative and 12 (54.5%) were Escherichia coli. An extended-spectrum β-lactamase phenotype was present in nine episodes. Among 14 Gram-negative episodes with susceptibility data, 71.4% were fluoroquinolone-resistant and 92.9% meropenem-susceptible; empirical therapy was active in 16 of 20 episodes (80.0%). No baseline covariate predicted BSI, and early BSI was not associated with overall survival (adjusted HR 0.75, 95% CI 0.34–1.64). Conclusions: Early bacterial BSI was predominantly Gram-negative and E. coli-driven, with frequent fluoroquinolone resistance but preserved carbapenem susceptibility. Contaminant adjudication substantially altered incidence and should be stated explicitly.
- 12 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2615
Open AccessEarly Bacterial Bloodstream Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Microbiology and Outcomes in a Single Turkish Center
Background/Objectives: Bloodstream infections (BSIs) are a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and reported incidence depends on how skin commensals are adjudicated. We describe the epidemiology, microbiology, risk factors, and survival impact of early (day 0–30) bacterial BSI at a Turkish transplant center. Methods: We retrospectively studied 155 consecutive allo-HSCT episodes in 153 adults (April 2017–January 2026). Single-isolate coagulase-negative staphylococci (CoNS) were classified as contaminants. Cumulative incidence was estimated with the Aalen–Johansen estimator and survival with day-30 landmark and time-dependent Cox models. Results: Bacterial BSI occurred in 20 episodes (30-day cumulative incidence 12.9%, 95% CI 8.2–18.7) at a median of 14 days; counting single-isolate CoNS would have raised incidence to 40.0%. Of 22 isolates, 15 (68.2%) were Gram-negative and 12 (54.5%) were Escherichia coli. An extended-spectrum β-lactamase phenotype was present in nine episodes. Among 14 Gram-negative episodes with susceptibility data, 71.4% were fluoroquinolone-resistant and 92.9% meropenem-susceptible; empirical therapy was active in 16 of 20 episodes (80.0%). No baseline covariate predicted BSI, and early BSI was not associated with overall survival (adjusted HR 0.75, 95% CI 0.34–1.64). Conclusions: Early bacterial BSI was predominantly Gram-negative and E. coli-driven, with frequent fluoroquinolone resistance but preserved carbapenem susceptibility. Contaminant adjudication substantially altered incidence and should be stated explicitly.
- Open Access
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3700
Serum Asprosin Concentrations and Severity in Acute Pancreatitis: A Prospective Case–Control Study with Serial Measurements
Background/Objectives: Asprosin is a fasting-induced glucogenic adipokine with pro-inflammatory effects in experimental models, but its behaviour in acute pancreatitis (AP) is unknown. In this exploratory study, we examined whether circulating asprosin differs between patients with AP and healthy controls, how it changes during hospitalisation and whether it is associated with disease severity. Methods: In this prospective case–control study, 82 patients with AP (of 183 screened, after exclusion of diabetes, hypertriglyceridaemia and morbid obesity) and 82 sex-matched healthy controls were enrolled. Serum asprosin was measured by ELISA at admission, 72 h and 120 h in patients and once in fasting controls. Severity was defined by the revised Atlanta classification. Because patients were older and heavier than controls, the group difference was adjusted for age, body mass index and sex and examined in post hoc matched subsamples. Results: Admission asprosin was 4.52 (2.94–5.89) ng/mL in patients and 3.55 (2.24–4.92) ng/mL in controls (p = 0.071); the ratio of geometric means adjusted for age, body mass index and sex was 1.17 (95% CI 0.85–1.61). Asprosin was higher in patients in post hoc age- and sex-matched pairs (median difference 1.91 ng/mL, 95% CI 0.24–3.78) but not in body mass index- and sex-matched pairs (0.96 ng/mL, −0.34 to 2.72). Asprosin changed little over five days and was not associated with moderately severe or severe AP (AUC 0.57, upper 95% confidence limits ≤0.71); only seven patients had severe AP. Conclusions: In this exploratory study, serum asprosin was modestly and non-significantly higher in patients with AP than in controls, and no statistically significant association with severity was detected. Residual confounding by age and body mass index, the exclusion of patients with diabetes or hypertriglyceridaemia (≥200 mg/dL) and the absence of in-house assay validation preclude firm conclusions. These data provide effect estimates for adequately powered, matched studies of asprosin in AP.
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3700
Open AccessSerum Asprosin Concentrations and Severity in Acute Pancreatitis: A Prospective Case–Control Study with Serial Measurements
Background/Objectives: Asprosin is a fasting-induced glucogenic adipokine with pro-inflammatory effects in experimental models, but its behaviour in acute pancreatitis (AP) is unknown. In this exploratory study, we examined whether circulating asprosin differs between patients with AP and healthy controls, how it changes during hospitalisation and whether it is associated with disease severity. Methods: In this prospective case–control study, 82 patients with AP (of 183 screened, after exclusion of diabetes, hypertriglyceridaemia and morbid obesity) and 82 sex-matched healthy controls were enrolled. Serum asprosin was measured by ELISA at admission, 72 h and 120 h in patients and once in fasting controls. Severity was defined by the revised Atlanta classification. Because patients were older and heavier than controls, the group difference was adjusted for age, body mass index and sex and examined in post hoc matched subsamples. Results: Admission asprosin was 4.52 (2.94–5.89) ng/mL in patients and 3.55 (2.24–4.92) ng/mL in controls (p = 0.071); the ratio of geometric means adjusted for age, body mass index and sex was 1.17 (95% CI 0.85–1.61). Asprosin was higher in patients in post hoc age- and sex-matched pairs (median difference 1.91 ng/mL, 95% CI 0.24–3.78) but not in body mass index- and sex-matched pairs (0.96 ng/mL, −0.34 to 2.72). Asprosin changed little over five days and was not associated with moderately severe or severe AP (AUC 0.57, upper 95% confidence limits ≤0.71); only seven patients had severe AP. Conclusions: In this exploratory study, serum asprosin was modestly and non-significantly higher in patients with AP than in controls, and no statistically significant association with severity was detected. Residual confounding by age and body mass index, the exclusion of patients with diabetes or hypertriglyceridaemia (≥200 mg/dL) and the absence of in-house assay validation preclude firm conclusions. These data provide effect estimates for adequately powered, matched studies of asprosin in AP.
- 18 May 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (2) , 47-52
CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.
- 18 May 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (2) , 47-52
CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.